<DOC>
	<DOC>NCT02922231</DOC>
	<brief_summary>Primary: To characterize the safety of RIXUBIS when used under normal clinical care in South Korea. Secondary: To describe hemostatic effectiveness in subjects receiving RIXUBIS under normal clinical care in South Korea.</brief_summary>
	<brief_title>Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>1. Participants with congenital hemophilia B (FIX level â‰¤5%) 2. Participant or the participant's legally authorized representative has provided signed informed consent. 3. Participant is indicated for treatment according to the RIXUBIS Korean product leaflet. 1. Participants with known hypersensitivity or presence of any contraindication to RIXUBIS or its excipients including hamster protein 2. Participants with Disseminated Intravascular Coagulation (DIC) 3. Participants with signs of fibrinolysis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>